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http://ccforum.com/content/18/3/R100RESEARCH Open AccessElevated plasma thrombomodulin and
angiopoietin-2 predict the development of acute
kidney injury in patients with acute myocardial
infarction
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Introduction: Acute kidney injury (AKI) following acute myocardial infarction (AMI) is associated with unfavorable
prognosis. Endothelial activation and injury were found to play a critical role in the development of both AKI and
AMI. This pilot study aimed to determine whether the plasma markers of endothelial injury and activation could
serve as independent predictors for AKI in patients with AMI.
Methods: This prospective study was conducted from March 2010 to July 2012 and enrolled consecutive 132
patients with AMI receiving percutaneous coronary intervention (PCI). Plasma levels of thrombomodulin (TM), von
Willebrand factor (vWF), angiopoietin (Ang)-1, Ang-2, Tie-2, and vascular endothelial growth factor (VEGF) were
measured on day 1 of AMI. AKI was defined as elevation of serum creatinine of more than 0.3 mg/dL within 48 hours.
Results: In total, 13 out of 132 (9.8%) patients with AMI developed AKI within 48 hours. Compared with
patients without AKI, patients with AKI had increased plasma levels of Ang-2 (6338.28 ± 5862.77 versus
2412.03 ± 1256.58 pg/mL, P = 0.033) and sTM (7.6 ± 2.26 versus 5.34 ± 2.0 ng/mL, P < 0.001), and lower estimated
glomerular filtration rate (eGFR) (46.5 ± 20.2 versus 92.5 ± 25.5 mL/min/1.73 m2, P < 0.001). Furthermore, the areas
under the receiver operating curves demonstrated that plasma thrombomodulin (TM) and Ang-2 levels on day 1
of AMI had modest discriminative powers for predicting AKI development following AMI (0.796, P <0.001; 0.833,
P <0.001; respectively).
Conclusions: Endothelial activation, quantified by plasma levels of TM and Ang-2 may play an important role in
development of AKI in patients with AMI.Introduction
Acute kidney injury (AKI) is a common complication of
acute myocardial infarction (AMI). The incidence of AKI
ranged from 9.6 to 19% in hemodynamically stable AMI
patients [1-3] and up to more than 50% in AMI patients
with cardiogenic shock [4]. Worsening renal function
during AMI, even transient, is associated with adverse* Correspondence: smlin@gmail.com; pchu@adm.cgmh.org.tw
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reproduction in any medium, provided the oroutcome and long-term mortality [2,5]. The mechanism
of AKI in patients with AMI is multifactorial, including
underlying renal insufficiency, hemodynamic alterations,
changes in volume status, neurohormonal activation, and
medical therapies such as diuretics and agents that may
affect the renin–angiotensin–aldosterone axis, immune-
mediated damages, and the use of contrast medium [6].
Recent evidence suggests that endothelial injury of the
renal vasculature may play an important role in the
pathogenesis of both early and chronic ischemic AKI
[7]. Early alterations in peritubular capillary blood flow
during reperfusion have been documented to associate
with loss of normal endothelial cell function [7]. Several
molecules, such as thrombomodulin (TM) and angio-
poietins, were reported to be connected with endothelialThis is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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dominantly located at the vascular endothelium [10].
Once bound to thrombin, TM accelerates protein C acti-
vation, triggers its own proteolytic degradation, and re-
leases the resultant soluble form of thrombomodulin
(sTM) to serum [11]. Endothelial injury has been reported
to be the unique stimulation for sTM to be released from
the surfaces of endothelial cells [12]. Increased levels of
plasma sTM can therefore serve as a marker of endothelial
injury, and have been found to be associated with worse
outcomes in patients with acute coronary syndrome [13].
Furthermore, increased plasma levels of sTM have been
reported to be associated with kidney injury induced by
sepsis [14] and diabetes [15].
Angiopoietin (Ang)-1, Ang-2, and their endothelial
cell-specific tyrosine kinase receptor, Tie-2, interact with
vascular endothelial growth factor (VEGF) to mediate en-
dothelial activation. Ang-1 exerts protective effects and
limits activation of the endothelium by exogenous cy-
tokine. Ang-1 is anti-inflammatory by inhibiting VEGF-
induced blood-vessel formation and adhesion molecule
expression. Ang-1 also downregulates VEGF expression
and attenuates thrombin-induced permeability [16]. In
contrast, Ang-2 triggers an inflammatory response by acti-
vating the endothelium and increasing its permeability [8].
With the important roles of angiopoietins in endothelial
activation and vascular barrier breakdown being identified,
applicability of these molecules to serve as biomarkers of
critical illness was explored in several studies [17]. For ex-
ample, plasma levels of Ang-2, Tie-2, and VEGF but not
Ang-1 are found to be increased in patients with acute
coronary syndrome [18]. Moreover, circulating Ang-2 was
documented as a strong and independent predictor for
mortality of patients with dialysis-dependent AKI in the
ICU [19].
Although endothelial activation and injury have been
suggested to be significant in AKI caused by sepsis or
diabetes, what roles they may play in AKI development
following an AMI event have not been elucidated. This
pilot study aimed to determine whether the plasma mar-
kers of endothelial injury and activation could serve as
independent predictors for AKI in patients with AMI.Materials and methods
Study population
This prospective study was conducted from March 2010
to July 2012 and enrolled consecutive patients with AMI
receiving percutaneous coronary intervention (PCI). The
study was approved by the Institutional Review Board of
Chang Gung Memorial Hospital, Taiwan (Institutional
Review Board No. 99-0140B) and conformed to the te-
nets of the Declaration of Helsinki. All enrolled patients
provided informed consent.The inclusion criteria were patients with AMI recei-
ving PCI. Exclusion criteria were patients with chronic
kidney disease requiring dialysis or with previous kidney
transplantation. Patients with preexisting renal impair-
ment were included in the study.
AMI was diagnosed by the universal definition pub-
lished in 2007 [20]. AKI was diagnosed according to the
definition proposed by the AKI Network [21]; that is, an
increase in the level of serum creatinine >0.3 mg/dl within
48 hours.
Baseline and procedural data
The demographic data of patients were collected on the
first day of AMI. The collected information included bo-
dy mass index, blood pressure, heart rate, smoking sta-
tus, and Killip class in addition to previous diagnosis of
hypertension, hyperlipidemia, diabetes, and coronary ar-
tery disease. The left ventricular ejection fraction (LVEF)
acquired by modified Simpson’s method with echocardi-
ography was obtained on admission.
Patients’ serum troponin I and creatine kinase-MB levels
were measured on admission and every 8 hours. The peak
creatine kinase-MB level was used in the statistical ana-
lysis. The estimated glomerular filtration rate (eGFR) was
calculated by the Modification of Diet in Renal Disease
formula [22]. High-sensitive C-reactive protein (hsCRP),
hemoglobin, platelet, and leukocyte counts were measured
on admission.
The PCI procedure was performed according to con-
temporary interventional guidelines. Patients were pre-
treated with standard-dose unfractionated heparin, aspirin
and clopidogrel, followed by the treatment including anti-
platelet therapy, lipid-lowering and cardioprotective drugs
according to current treatment guidelines [23]. The door-
to-balloon time, use of the drug-eluting or bare metal
stent, and the amount of contrast medium used in the
index procedure were recorded. Number of vessels in-
volved was defined with binary fashion; that is, the severity
of ≥50% stenosis would be regarded as significant.
Enzyme-linked immunosorbent assay
Plasma was collected from blood taken on admission.
The concentrations of sTM, von Willebrand factor, Ang-1,
Ang-2, Tie-2, and VEGF were determined by enzyme-
linked immunosorbent assay (R&D system, Minneapolis,
MN, USA) following the manufacturers’ instructions. The
measured values were compared between patients with
and without AKI.
Statistical analysis
All data were expressed as mean ± standard deviation
or percentage. As the distribution of most continuous
variables was skewed, nonparametric analyses were
performed. Comparison of continuous and nominal
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Mann–Whitney test and the chi-square test, respect-
ively. Receiver operating characteristic (ROC) curves
for day 1 plasma levels of Ang-2 and sTM to predict the
development of AKI were plotted and the respective
areas under the curves were calculated. P < 0.05 using a
two-sided test was considered statistically significant.
All analyses were carried out using the SPSS software
package, version 20.0 (SPSS, Inc., Chicago, IL, USA).
Results
One hundred and thirty-two patients who were diag-
nosed with AMI from March 2010 to July 2012 were
consecutively recruited for this study. Among them, 130
patients had acute ST-elevation myocardial infarction
and two patients had non-ST-elevation myocardial in-
farction. Thirteen of 132 (9.8%) patients developed AKI
within 48 hours. The demographic characteristics, bio-
markers, clinical presentation, and infarction type are
presented in Table 1. Compared with patients without
AKI, patients with AKI had higher incidence of hyper-
tension (84.6 vs. 44.5%, P = 0.008) and coronary artery
disease history (53.8 vs. 10.9%, P < 0.001), increased per-
ipheral blood leukocyte count (15,954 ± 8,647 vs. 11,160 ±
3,646/ml, P <0.001), plasma levels of hsCRP (44.86 ± 63.82
vs. 13.44 ± 28.38 mg/l, P = 0.001), Ang-2 (6,338.28 ±
5,862.77 vs. 2,412.03 ± 1,256.58 pg/ml, P = 0.033) and sTM
(7.6 ± 2.26 vs. 5.34 ± 2.0 ng/ml, P < 0.001). In addition, pa-
tients with AKI had higher Killip class (61.5 vs. 20.2% ≥3,
P = 0.001), lower eGFR (46.5 ± 20.2 vs. 92.5 ± 25.5 ml/mi-
nute/1.73 m2, P < 0.001), and less use of clopidogrel (84.6
vs. 99.2%, P =0.026). No significant differences were found
for age, gender, diabetes mellitus, hyperlipidemia, smoking
status, body mass index, blood pressure, heart rate, door-
to-balloon time, amount of contrast medium, LVEF, he-
moglobin, platelet count, hsCRP, creatine kinase-MB,
VEGF, von Willebrand factor, Ang-1, Ang-2, number of
vessels involved, type of stent used, aspirin, angiotensin-
converting enzyme inhibitor/angiotensin receptor blocker,
and statin between the two groups. Multivariate analysis
was not performed due to the low incidence of AKI events
in the study cohort.
In the study population, 109 patients had eGFR >
60 ml/minute/1.73 m2 while 24 patients had eGFR <
60 ml/minute/1.73 m2. The incidence of AKI in pa-
tients with eGFR < 60 ml/minute/1.73 m2 (10/24, 41.7%)
was significantly increased compared with those with
eGFR > 60 ml/minute/1.73 m2 (3/109, 2.8%; odds ratio,
37.18; 95% confidence interval, 6.61 to 111.7; P < 0.001).
In patients with eGFR < 60 ml/minute/1.73 m2, plasma le-
vels of Ang-2 (7,374 ± 6,357 pg/ml, n = 10 vs. 2,945 ±
1,314 pg/ml, n = 13; P = 0.023) and TM (7.84 ± 1.95 ng/ml,
n = 10 vs. 5.99 ± 1.32 ng/ml, n = 13; P =0.013) were in-
creased in patients with AKI compared with those without(Figure 1). In contrast, plasma levels of Ang-2 (2,886 ±
1,077 pg/ml, n = 3 vs. 2,347 ± 1,240 pg/ml, n = 106; P =
0.458) and TM (6.8 ± 3.52 ng/ml, n = 3 vs. 5.26 ±
2.05 ng/ml, n = 106; P =0.209) were similar in patients
with and without AKI if their eGFR was > 60 ml/minute/
1.73 m2 (Figure 2).
As shown in Table 2, the ROC curves of Ang-2 and
sTM were plotted in predicting development of AKI
48 hours following AMI. Areas under the ROC curves
showed that plasma levels of Ang-2 and TM on day 1
had modest discriminative powers in development of AKI
(0.833; 95% confidence interval, 0.737 to 0.928; P <0.001;
and 0.796; 95% confidence interval, 0.681 to 0.911;
P <0.001, respectively). The cutoff values for Ang-2 and
sTM in predicting AKI were 2,578.4 pg/ml and 5.44 ng/ml,
respectively.
The plasma levels of sTM in patients with multivessel
disease (5.706 ± 0.332 ng/ml) were significantly lower
than those in patients without (6.488 ± 0.302 ng/ml, P =
0.047). Compared with patients with Killip class 1, those
with Killip class 2 to 4 had significantly higher Ang-2
levels (3,969 ± 673.2 vs. 2,773 ± 254.2 pg/ml, P = 0.009).
The plasma concentration of Ang-2 in patients with
LVEF < 45% (3,786 ± 566.8 pg/ml) was significantly higher
than that in patients with LVEF > 45% (2,856 ± 211.3 pg/ml,
P = 0.021).
Discussion
The study demonstrated that 13 of 132 (9.8%) patients
developed AKI 48 hours after the event of AMI. Com-
pared with patients without AKI, patients with AKI had
higher leukocyte count, plasma levels of eGFR, hsCRP,
sTM, and Ang-2. In patients with eGFR < 60 ml/minute/
1.73 m2, plasma levels of Ang-2 and TM were increased
in patients with AKI compared with those without. Pa-
tients with multivessel disease had higher levels of plasma
sTM than those without. Patients with impaired left ven-
tricular function had increased Ang-2 levels.
Previous studies have shown an increase of the periph-
eral leukocyte count and hsCRP levels in patients with
AMI-associated AKI [24,25]. Consistently, our data dem-
onstrated that these two inflammation-related markers
were increased in AMI patients with AKI. This result is
suggestive of the role(s) that inflammation may play in
mediating the development of AKI in AMI patients. In-
creased C-reactive protein is associated with platelet and
clotting system activation, and decreased renal blood
flow [26]. Increased C-reactive protein levels in AMI pa-
tients were therefore associated with development of
AKI. Furthermore, C-reactive protein can mediate en-
hanced expression of adhesion molecules and plasmino-
gen activator inhibitor-1. This may cause endothelium
dysfunction and subsequent a proinflammatory, pro-
thrombotic, and vasoconstrictive state of the endothelial
Table 1 Demography, clinical presentation, biomarkers, and infarction characteristics of patients with acute myocardial
infarction
All patients With AKI Without AKI P value
(n = 132) (n = 13) (n = 119)
Demography
Age (years) 59 ± 13 66 ± 14 59 ± 13 0.067
Male gender 118 (89.4%) 12 (92.3%) 106 (89.1%) 1.000
Hypertension 64 (48.5%) 11 (84.6%) 53 (44.5%) 0.008
Diabetes 36 (27.3%) 6 (46.2%) 30 (25.2%) 0.107
Hyperlipidemia 33 (25%) 3 (23.1%) 30 (25.2%) 1.000
Current smoker 84 (63.6%) 8 (61.5%) 76 (63.9%) 0.868
CAD history 20 (15.2%) 7 (53.8%) 13 (10.9%) <0.001
Body mass index (kg/m2) 25.6 ± 3.7 25.7 ± 3.6 25.6 ± 3.7 0.974
Clinical presentation
Door-to-balloon time (minutes) 74 ± 42 73 ± 11 74 ± 44 0.909
Systolic blood pressure (mmHg) 139 ± 39 136 ± 66 140 ± 36 0.852
Diastolic blood pressure (mmHg) 89 ± 25 87 ± 48 89 ± 21 0.883
Heart rate (beats/minute) 77 ± 21 89 ± 41 75 ± 18 0.270
Killip class ≥3 32 (24.2%) 8 (61.5%) 24 (20.2%) 0.001
Killip class
1 87 (65.9%) 3 (23.1%) 84 (70.6%)
2 13 (9.8%) 2 (15.4%) 11 (9.2%)
3 10 (7.6%) 4 (30.8%) 6 (5.0%)
4 22 (16.7%) 4 (30.8%) 18 (15.1%)
LVEF (%) 55 ± 13 46 ± 21 56 ± 11 0.112
eGFR (ml/minute/1.73 m2) 88.0 ± 28.5 46.5 ± 20.2 92.5 ± 25.5 <0.001
Contrast medium (ml) 249 ± 61 254 ± 33 248 ± 63 0.846
Hematology and biomarkers of myocardial necrosis and inflammation
Leukocyte count (/ml) 11,632 ± 4,569 15,954 ± 8,647 11,160 ± 3,646 <0.001
Hemoglobin (g/dl) 14.7 ± 1.8 14.1 ± 1.9 14.8 ± 1.8 0.195
Platelet count (1,000/ml) 226 ± 67 271 ± 139 222 ± 53 0.222
Peak creatine kinase-MB (units/l) 280 ± 254 327 ± 495 275 ± 219 0.734
hsCRP (mg/l) 15.7 ± 27.4 44.86 ± 63.82 13.14 ± 20.38 0.001
Biomarkers of endothelial injury
VEGF (pg/ml) 258.03 ± 373.74 398.10 ± 346.13 241.92 ± 374.86 0.154
Tie-2 (ng/ml) 17.50 ± 8.89 19.02 ± 6.43 17.33 ± 9.13 0.519
vWF (MU) 716.36 ± 216.37 734.31 ± 273.64 714.40 ± 261.12 0.795
Thrombomodulin (ng/ml) 5.56 ± 2.1 7.6 ± 2.26 5.34 ± 2.0 <0.001
Angiopoietin-1 (pg/ml) 29,082.88 ± 20,898.78 36,070.09 ± 21,123.43 28,319.57 ± 20,821.49 0.228
Angiopoietin-2 (pg/ml) 2,798.71 ± 2,439.26 6,338.28 ± 5,862.77 2,412.03 ± 1,256.58 0.033
Infarction type
Culprit vessel
LMCA 1 (1.3%) 0 1 (0.9%) 1.000
LAD 69 (52.3%) 8 (61.5%) 61 (51.3%) 0.481
LCx 10 (7.6%) 0 10 (8.4%) 0.597
RCA 52 (39.4%) 5 (38.5%) 47 (39.5%) 0.942
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Table 1 Demography, clinical presentation, biomarkers, and infarction characteristics of patients with acute myocardial
infarction (Continued)
Grafts 0 0 0
Multivessel disease 63 (47.7%) 8 (51.5%) 55 (46.2%) 0.294
Number of involved vessels
1 68 (51.5%) 5 (38.5%) 29 (24.4%)
2 38 (28.8%) 4 (30.8%) 22 (18.5%)
3 25 (18.9%) 2 (15.4%) 17 (14.3%)
Stenting
Use of DES 75 (56.8%) 5 (38.5%) 70 (58.8%) 0.159
Use of BMS 36 (27.3%) 3 (23.1%) 33 (27.7%) 1.000
Medications
Aspirin 127 (96.2%) 12 (92.3%) 115 (96.6%) 0.410
Clopidogrel 129 (97.7%) 11 (84.6%) 118 (99.2%) 0.026
Beta-blocker 120 (90.9%) 10 (76.9%) 110 (92.4%) 0.098
ACEI/ARB 96 (72.7%) 11 (84.6%) 85 (71.4%) 0.513
Statin 122 (92.4%) 11 (84.6%) 111 (93.2%) 0.256
Data presented as mean ± standard deviation or n (%). ACEI/ARB, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; AKI, acute kidney injury;
BMS, bare metal stent; CAD, coronary artery disease; DES, drug-eluting stent; eGFR, estimated glomerular filtration rate; hsCRP, high-sensitive C-reactive protein;
LAD, left anterior descending coronary artery; LCx, left circumflex coronary artery; LMCA, left main coronary artery; LVEF, left ventricular ejection fraction; RCA, right
coronary artery; VEGF, vascular endothelial growth factor; vWF, von Willebrand factor.
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has shown that leukodepletion reduced postcardiopul-
monary bypass renal injury in patients who underwent
coronary bypass surgery [28]. Taken together, the inflam-
matory response following AMI may play a significant
role in developing AKI.
We also showed that plasma levels of sTM were in-
creased in AMI patients with AKI development. ROC
curves demonstrated that the day 1 sTM level had a mo-
dest discriminative power in predicting AKI develop-
ment within 48 hours after AMI. Since sTM has been
shown to be a specific marker of endothelial injury, ourFigure 1 Concentrations of angiopoietin-2 in patients with and
without acute kidney injury. Open bars, patients without acute
kidney injury (AKI); solid bars, patients with AKI. *P < 0.05 compared
with patients without AKI in the subgroup of estimated glomerular
filtration rate (eGFR) < 60 ml/minute/1.73 m2. Data expressed as
mean ± standard deviation.data indicated that endothelial injury may be an essential
mediator of kidney injury following AMI [12]. Endothe-
lial injury may be triggered by altered hemodynamics,
hypoxia, and inflammatory response following AMI. The
injured endothelial cells in turn exert enhanced procoa-
gulatory properties and may be responsible for the forma-
tion of a large number of microthrombotic foci, leading to
organ microcirculation failures and subsequent complete
organ failure [29]. Increased sTM is related to the severity
of coronary disease, stroke, and peripheral occlusive arter-
ial disease [30], and possibly associates with recurrence inFigure 2 Concentrations of thrombomodulin in patients with
and without acute kidney injury. Open bars, patients without
acute kidney injury (AKI); solid bars, patients with AKI. *P < 0.05
compared with patients without AKI in the subgroup of estimated
glomerular filtration rate (eGFR) < 60 ml/minute/1.73 m2. Data
expressed as mean ± standard deviation.
Table 2 Acquisition of the areas under the receiver operating characteristic curves for day 1 plasma levels of
angiopoietin-2 and thrombomodulin to predict development of acute kidney injury within 48 hours after acute
myocardial infarction
AUROC 95% CI P value Cutoff value Sensitivity Specificity
Angiopoietin-2 0.833 0.737 to 0.928 <0.001 2,578.4 pg/ml 0.846 0.689
Thrombomodulin 0.796 0.681 to 0.911 <0.001 5.44 ng/ml 0.846 0.622
AUROC, area under the receiver operating characteristic curves; CI, confidence interval.
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nection between asymptomatic vascular atherosclerosis
and sTM has been established previously [32]. In the
present study, we showed that patients with multivessel
disease, who may have a higher degree of vascular athero-
sclerosis or endothelial injury [33], had a significantly
higher level of sTM than those without. The Ang–Tie2
signaling pathway in endothelial cells was reported to
enhance local leukocyte recruitment and promote endo-
thelial injury. This pathway may participate in vascular
activation, proinflammatory responses, and leukocyte re-
cruitment through complex signaling transduction in en-
dothelial cells [34]. Previous studies have demonstrated
that plasma levels of Ang-2, Tie-2, and VEGF but not of
Ang-1 were increased in patients with AMI [18]. Elevated
levels of Ang-2 were documented as an effective bio-
marker for AMI. Emerging evidence has indicated that
Ang-2 is involved in critical illness-induced organ dys-
function [17]. Data in mice studies also showed that over-
expression of Ang-2 in podocytes causes proteinuria,
apoptosis of glomerular endothelium, and kidney injury
[35]. As far as we can find from the literature, our data are
the first to report that Ang-2 can serve as an independent
clinical predictor of the development of AKI in patients
with AMI. Furthermore, we demonstrated that poor car-
diac function assessed by Killip class and echocardiog-
raphy was related to the increased plasma level of Ang-2.
This observation is consistent with a previous report
showing that plasma levels of Ang-2 are progressively in-
creased in patients with functional and hemodynamic de-
cline of the heart [36]. Activation of endothelial cells, as
indicated by plasma Ang-2 levels, may therefore be in-
volved in development of AKI and heart failure in patients
with AMI.
The plasma sTM and Ang-2 levels were increased in
AMI patients with AKI. The corresponding areas un-
der the ROC curve showed that both plasma sTM and
Ang-2 levels on day 1 of AMI had modest discriminative
power to predict AKI 48 hours after AMI. If further con-
firmed by large-scale prospective studies, these findings
have great potential clinically. Patients may have sTM
and Ang-2 measured early after AMI. If the levels are
high, efforts to identify and treat the modifiable factors
associated with kidney injury should be prompted. Pa-
tients may thus have better clinical outcome when the
potential AKI is identified earlier than its onset andprevented beforehand. Further studies are warranted to
evaluate the applicability of monitoring plasma sTM
and Ang-2 levels in the management of AMI patients.
There are limitations of this study. First, the study is
limited by the small sample size and single-center de-
sign. In addition, only a selective subgroup of AMI pa-
tients who received primary PCI was recruited. Patients
who were not candidates for primary PCI due to severe
comorbidities, unstable hemodynamic parameters, or de-
lay diagnosis of AMI were excluded. Whether these po-
tential markers could provide similar predictive capability
to other subpopulations of patients with AMI remains to
be investigated.
In summary, AMI patients with AKI had increased
leukocyte count, plasma levels of hsCRP, sTM, and Ang-
2 but decreased eGFR compared with those without
AKI. The measurements taken on day 1 of AMI have
modest discriminative power for predicting AKI 48 hours
after AMI. Our data suggest that endothelial activation
and injury play a significant role in mediating kidney in-
jury in patients with AMI.
Conclusion
AKI following AMI results in unfavorable prognosis, be-
ing related to both endothelial activation and injury. Our
study demonstrates that the plasma markers, TM and
Ang-2 levels on the first day of AMI have modest dis-
criminative powers for prediction, and could serve as in-
dependent predictors for AKI in patients with AMI.
Key messages
 AKI is a common complication of AMI.
 Endothelial activation and injury were found to play
a critical role in the development of both AKI and
AMI.
 Endothelial activation, quantified by plasma levels of
TM and Ang-2, may play an important role in the
development of AKI in patients with AMI.
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